Vertex trial for hypoglycaemia therapy shows early promise
New data now reveals significant increases in the blood glucose time-in-range compared to baseline, following VX-880 dosage
Read More
Tag: VX-880
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
